This multicenter retrospective study at 22 centers in Japan using electronic medical record data aimed to compare the effectiveness and safety of CTLA-4 regimens (ipilimumab plus nivolumab with or without chemotherapy) versus non-CTLA-4 regimens (pembrolizumab or atezolizumab plus chemotherapy) as first-line treatmen...
D. Murata, Koichi Azuma, K. Murotani et al.· Scientific Reports· 0 citations
Introduction Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant lung cancer is associated with a poor prognosis, underscoring the need for effective pharmacological treatments. An exploratory subgroup analysis of IMpower150 suggested potential clinical benefit of the atezolizumab-containing regimen in KRAS-mutant...
Masaki Ishida, T. Yamada, Riko Kamada et al.· Frontiers in Immunology· 0 citations
INTRODUCTION
First-line osimertinib monotherapy remains a standard treatment for advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), although intensified regimens improve outcomes at the cost of an increased toxicity and treatment burden. We characterized pretreatment clinical f...
Masaki Ishida, T. Yamada, O. Yamaguchi et al.· Journal of Thoracic Oncology· 0 citations
Background Osimertinib is the standard first-line treatment for non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation. Erlotinib plus an angiogenesis inhibitor (erlotinib+A) has demonstrated efficacy in controlling malignant pleural effusion (MPE) through reduction of vascular...
T. Hata, T. Yamada, Koji Mikami et al.· Translational Lung Cancer Re...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.